ClinicalTrials.gg
RecruitingNCT06940336Updated Jul 30, 2025

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

A Phase 4 interventional study of Tafamidis Meglumine Soft Capsules in Transthyretin Amyloid Polyneuropathy, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Amyloid Neuropathies, Familial with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Amyloid Neuropathies, Familial · China.

Started
2025
with 2 others
Phase 4
2 of 10
1 open now
Registered
5th of 10
by date
Lead sponsor
1 of 10
Qilu Pharmaceutical Co., Ltd.

Among the 10 studies in Amyloid Neuropathies, Familial with a site in China, this one is one of 3 that started in 2025, is one of 2 in phase 4, and was the 5th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

8 of the 10 studies in Amyloid Neuropathies, Familial with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Amyloid Neuropathies, Familial with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy

03

Conditions studied

  • Transthyretin Amyloid Polyneuropathy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants between the ages of 18 and 80 years.
  • Participant has amyloid deposits confirmed by (Biopsy must have been performed within 5 years prior to enrollment).
  • Participant must have a TTR mutation that is associated with ATTR-PN (TTR mutation test must have been performed within 5 years prior to enrollment).
  • Participant has peripheral neuropathy at screening.
  • Participant has a Performance Status Score ≥50.
  • Stages of disease according to symptom severity-stage 1.

Exclusion criteria

Exclusion Criteria:

  • Participant has other causes of amyloidosis, such as light chain amyloidosis, AA amyloidosis.
  • Participant has used tafamidis within 2 months prior to enrollment.
  • Participant has used diflunisal, patisiran, inotersen, or other agents for familial amyloidosis within 30 days prior to enrollment or plan to use them during the study period.
  • Participant has used non-protocol NSAIDs more than 4 times within 30 days prior to enrollment or plan to use them more than 4 times per month during the study period.
  • Participant has used doxycycline,tauroursodeoxycholate within 14 days prior to enrollment or plan to use them during the study period.
  • Participant has sensory motor neuropathy caused by other causes, such as chronic inflammatory demyelinating polyradiculopathy, chronic idiopathic axonal neuropathy, diabetic neuropathy, chronic alcoholic neuropathy, paraneoplastic neuropathy,Guillain-Barre syndrome, vitamin B12 deficiency.
  • Participant has received liver or any other organ except cornea transplantation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Tafamidis Meglumine Soft Capsules

    Drug: Tafamidis Meglumine Soft Capsules

Interventions

  • DrugTafamidis Meglumine Soft Capsules

    20 mg orally once daily for 72 weeks

06

What researchers measure

Primary outcomes

  1. Change from Baseline Neuropathy Impairment Score-Lower Limb (NIS-LL) at Week 72

    Change from Baseline Neuropathy Impairment Score-Lower Limb (NIS-LL) at Week 72

    Time frame: Baseline to 72 Weeks

Secondary outcomes

  1. Change from Baseline NIS-LL at Week 24 and Week 48

    Change from Baseline NIS-LL at Week 24 and Week 48

    Time frame: Baseline to 24 and 48 Weeks

  2. Change from Baseline Modified Body Mass Index(mBMI) at Week 4, Week 8, Week 12,Week 24, Week 36,Week 48 and Week 72

    Change from Baseline Modified Body Mass Index(mBMI) at Week 4, Week 8, Week 12,Week 24, Week 36,Week 48 and Week 72

    Time frame: Baseline to 4, 8, 12, 24, 36, 48 and 72 Weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jan 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 23, 2025
StartActual
Jun 19, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Feb 2028
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06940336
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Jun 19, 2025
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jul 30, 2025

Study contacts

chuanzhu yan, Doctor
Contact
zzl2002@medmail.com
18560082288

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion